Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis by 源��쁽�닔
Oncotarget79319www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 48
Downregulation of osteoprotegerin expression in metastatic 
colorectal carcinoma predicts recurrent metastasis and poor 
prognosis
Ahrim Moon1,*, Sung-Im Do2,*, Hyun-Soo Kim3, Youn-Wha Kim4
1Department of Pathology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 
Bucheon-si, Gyeonggi-do, Republic of Korea
2Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic 
of Korea
3Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
4Department of Pathology, Kyung Hee University School of Medicine, Seoul, Republic of Korea
*These authors have contributed equally to this work
Correspondence to: Hyun-Soo Kim, email: hyunsookim@yuhs.ac
Keywords: osteoprotegerin, downregulation, colorectal carcinoma, recurrent metastasis, immunohistochemistry
Received: August 25, 2016    Accepted: September 30, 2016    Published: October 15, 2016
ABSTRACT
We recently reported the downregulation of osteoprotegerin expression in primary 
colorectal carcinoma and its significant association with aggressive oncogenic behavior, 
which suggest that this process contributes to colorectal carcinoma development 
and progression. In this study, we used immunohistochemical staining to evaluate 
osteoprotegerin expression in 81 colorectal liver metastasis tissue samples and 
investigated its possible association with the clinicopathological characteristics 
and outcomes of patients with colorectal liver metastasis. These tissues exhibited 
significantly reduced expression of osteoprotegerin compared to primary colorectal 
carcinomas and normal colorectal mucosa. This reduced expression was significantly 
associated with the extent of colorectal liver metastasis, including multiplicity of 
metastatic tumors, involvement of the bilateral hepatic lobes, and higher histological 
grade. In addition, reduced osteoprotegerin expression was an independent significant 
predictor of recurrent liver metastasis and prognostic factor for reduced patient survival. 
These findings suggest that osteoprotegerin expression may be a novel predictor of 
recurrent liver metastasis and a prognostic biomarker in patients with colorectal liver 
metastasis. Patients harboring colorectal liver metastasis with reduced osteoprotegerin 
expression should be carefully monitored after hepatic resection for colorectal liver 
metastasis to enable early detection of potentially resectable metastatic recurrences.
INTRODUCTION
Colorectal carcinoma is the fourth most common 
cancer in Western countries and the second leading cause 
of cancer-related deaths in Europe and North America 
[1, 2]. In Korea, colorectal carcinoma is the third most 
common cancer, after thyroid carcinoma and stomach 
carcinoma, and is the fourth leading cause of cancer-
related deaths [3]. Despite major advances in surgical 
techniques and chemotherapeutic agents, the prognosis 
of colorectal carcinoma patients remains poor due to 
development of distant metastasis and recurrence [4]. 
The liver is the most common site of metastasis for 
colorectal carcinoma; more than 50% of patients with 
primary colorectal carcinoma will develop liver metastasis 
during their lifetimes [1, 2, 5]. Untreated colorectal liver 
metastasis has poor prognosis with a median survival of 
6-12 months [4]. Evidence from numerous retrospective 
and comparative studies indicates that hepatic resection 
is the best potential curative treatment for colorectal liver 
metastasis that promotes long-term survival [6]. Hepatic 
resection for colorectal liver metastasis is associated with 
a 5-year survival rate of 25–51% [7].
Identification of patients at high risk for liver 
metastasis is essential to determine candidates 
for hepatic resection but has previously relied on 
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assessment of conventional pathological characteristics 
of colorectal carcinoma, including invasion depth, 
lymph node metastasis, and stage. However, the current 
tumor-node-metastasis staging system is limited, as 
it cannot offer a prognosis for individual patients [4]. 
Emerging strategies designed to increase the proportion 
of patients who are candidates for hepatic resection have 
been introduced in clinical practice, but most patients 
with colorectal liver metastasis are not candidates for 
this procedure [2]. To improve the outcome of patients 
with colorectal carcinoma with or without subsequent 
liver metastasis, identifying cancer-related genes as 
predictive and prognostic biomarkers for personalized 
therapy is critical.
Osteoprotegerin, a secreted member of the 
tumor necrosis factor receptor superfamily, has many 
biological functions, such as a potent inhibitor of 
osteoclastic bone resorption and a potential therapeutic 
agent for treatment of osteoporosis [8]. In addition 
to its role in bone metabolism, osteoprotegerin is 
involved in the development and progression of several 
human malignancies [4, 9–16]. We recently reported 
that osteoprotegerin expression is downregulated in 
primary colorectal carcinoma cell lines and tissues. This 
reduction is significantly associated with aggressive 
oncogenic behavior of colorectal carcinoma, including 
higher histological grade, lymph node metastasis, liver 
metastasis, advanced stage, and vascular invasion 
[4]. Furthermore, osteoprotegerin expression is an 
independent predictor of reduced survival of colorectal 
carcinoma patients [4].
Existing evidence for osteoprotegerin’s important 
role in tumor progression and metastasis of colorectal 
carcinoma prompted us to examine its expression 
in colorectal liver metastasis tissue samples 
and to investigate its potential relationship with 
clinicopathological characteristics and clinical outcomes 
of patients with colorectal liver metastasis. As a result, 
we identified independent predictors for recurrent 
liver metastasis that could facilitate the identification 
of patients at increased risk for developing metastatic 
recurrence.
RESULTS
Patient demographics
Primary colorectal carcinoma tissue and the 
corresponding colorectal liver metastasis tissue samples 
were obtained from 81 patients. The median patient age was 
60 years (range: 29–76 years), and 51.9% (42/81) of patients 
were aged 60 years or older. The study group included 56 
males and 25 females. Numbers of metastatic tumors per 
patient were as follows: 1 in 56.8% (46/81), 2 in 22.2% 
(18/81), 3 in 8.6% (7/81), and 4 or more in 12.3% (10/81) of 
patients. The median size of metastatic tumors was 2.5 cm; 
46 (56.8%) patients had metastatic tumors with a maximum 
diameter of 2.5 cm or greater. Histological grades of primary 
colorectal carcinoma were 1 (well-differentiated) in 17.3% 
(14/81), 2 (moderately-differentiated) in 79.0% (64/81), 
and 3 (poorly-differentiated) in 3.7% (3/81) of patients. The 
microsatellite instability (MSI) status of primary colorectal 
carcinoma was available in 84.0% (68/81) of patients and 
revealed that 6 (8.8%) of these 68 patients had MSI. Forty-
nine (60.5%) patients developed recurrent liver metastasis 
after hepatic resection.
Downregulation of osteoprotegerin expression 
in primary colorectal carcinoma and colorectal 
liver metastasis
We measured osteoprotegerin expression in normal 
colorectal mucosa, primary colorectal carcinomas, 
and colorectal liver metastasis tissue samples using 
immunohistochemistry. Osteoprotegerin immunoreactivity 
was predominantly cytoplasmic, although weak nuclear 
staining was noted in some tumor cells. In a few 
cases that showed strong osteoprotegerin expression 
in tumor cells, faint osteoprotegerin expression was 
noted in the extracellular matrix or connective tissue. 
Representative photomicrographs of osteoprotegerin 
immunostaining in normal colorectal mucosa, primary 
colorectal carcinomas, and colorectal liver metastasis 
tissues are shown in Figure 1. In 18 normal colorectal 
mucosal tissue samples, strong, uniform osteoprotegerin 
Figure 1: Osteoprotegerin immunoreactivity in normal colorectal mucosa, primary colorectal carcinoma, and 
colorectal liver metastasis. Representative photomicrographs are shown. Original magnification, 100×.
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immunoreactivity was observed in the cytoplasm of 
epithelial cells. Among the primary colorectal carcinoma 
tissues, reduced osteoprotegerin expression was observed 
in 61.7% (50/81) of tumor tissue samples. Osteoprotegerin 
immunoreactivity was moderate in 38.3% (31/81), weak 
in 32.1% (26/81), and absent in 29.6% (24/81) of primary 
colorectal carcinoma samples. Reduced osteoprotegerin 
expression was observed in 75.3% (61/81) of metastatic 
tissue samples. Osteoprotegerin immunoreactivity was 
moderate in 24.7% (20/81), weak in 32.1% (26/81), and 
absent in 43.2% (35/81) of colorectal liver metastasis 
samples. Osteoprotegerin expression in colorectal liver 
metastases was significantly decreased compared to that 
in primary colorectal carcinoma tissue samples (P=0.036; 
Table 1).
Relationship of osteoprotegerin 
immunoreactivity with the clinicopathological 
characteristics of colorectal liver metastasis
The association between osteoprotegerin expression 
and the clinicopathological characteristics of colorectal 
liver metastasis patients is illustrated in Table 2. We 
observed significant inverse relationships between 
osteoprotegerin expression and multiplicity of metastatic 
tumors (P<0.001), bilobar involvement of metastatic 
tumors (P=0.046), higher histological grade of primary 
colorectal carcinoma (P<0.001), and occurrence of 
recurrent liver metastasis (P<0.001).
Predictive value of osteoprotegerin expression 
for recurrent liver metastasis
Multiplicity of metastatic tumors (P<0.001), bilobar 
involvement of metastatic tumors (P=0.007), and reduced 
osteoprotegerin expression (P<0.001) were significantly 
associated with the recurrence of colorectal liver 
metastasis (Table 3). To identify the independent predictive 
factors for recurrent liver metastasis development, 
these three covariates were included in a multivariate 
logistic regression analysis. Multiplicity of metastatic 
tumors (P=0.002; relative risk=7.145; 95% confidence 
interval=2.015-25.337) and reduced osteoprotegerin 
expression (P=0.012; relative risk=5.425; 95% confidence 
interval=1.443-20.397) were independently predicted 
recurrent liver metastasis in our study group.
Prognostic significance of osteoprotegerin 
expression for colorectal liver metastasis
The prognostic value of osteoprotegerin expression 
for hepatic colorectal metastasis was evaluated. 
Complete data were available for all 81 patients. Forty-
nine (60.5%) patients died prior to their final follow-
up visit. A univariate survival analysis showed that the 
multiplicity of metastatic tumors (P<0.001), bilobar 
involvement of metastatic tumors (P=0.002), recurrent 
liver metastasis (P<0.001), and reduced osteoprotegerin 
expression (P<0.001) were significant predictors of poor 
prognosis (Table 4). The median survival duration of 
patients whose tumors exhibited reduced osteoprotegerin 
expression was 34 months compared to 92 months in 
patients with preserved osteoprotegerin expression 
(Figure 2). Patients with osteoprotegerin-preserved 
tumors had stable survival rates of 93.6% and 79.3% at 
3 and 5 years post-surgery, respectively, as shown by a 
Kaplan-Meier plot. In contrast, patients with reduced 
osteoprotegerin expression experienced a rapid decline 
in survival during the observation period. Survival rates 
were 43.6% at 3 years and 27.1% at 5 years post-surgery 
in patients with osteoprotegerin-reduced colorectal liver 
metastasis.
We also conducted multivariate survival analysis 
using a Cox proportional hazard regression model. 
Osteoprotegerin expression (P=0.011; hazard ratio=2.894; 
95% confidence interval=1.272–6.585) and recurrent liver 
metastasis (P=0.013; hazard ratio=2.401; 95% confidence 
interval=1.203–4.794) were independent prognostic 
factors influencing overall survival (Table 4). This analysis 
demonstrated that reduced osteoprotegerin expression was 
associated with a significant hazard ratio of 2.894, which 
was greater than the risk associated with recurrent liver 
metastasis (2.401).
Table 1: Differences in osteoprotegerin expression between primary colorectal carcinoma and colorectal liver 
metastasis
Category   
Number of cases (%)
P value   
Total  
Osteoprotegerin expression status
Reduced Preserved
0 1+ 2+ 3+
Colorectal liver metastasis 81 35 (43.2) 26 (32.1) 20 (24.7) 0 (0.0) 0.036*
Primary colorectal carcinoma 81 24 (29.6) 26 (32.1) 31 (38.3) 0 (0.0)  
*Statistically significant.
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DISCUSSION
We determined that colorectal liver metastasis 
tissues exhibit significantly reduced osteoprotegerin 
expression compared to primary colorectal carcinomas 
and normal colorectal mucosa tissues. This finding is 
consistent with our recent observation of significantly 
decreased osteoprotegerin expression in 68.4% of primary 
colorectal carcinoma cases but none in normal colorectal 
mucosa [4]. The frequency of reduced osteoprotegerin 
expression in primary colorectal carcinomas was similar 
to that demonstrated in our previous study. We also saw 
a significant association between reduced osteoprotegerin 
expression and the multiplicity and bilobar involvement 
of metastatic tumors and the occurrence of recurrent liver 
metastasis, which corroborates our previous findings 
that reduced osteoprotegerin expression is significantly 
associated with aggressive oncogenic behavior in primary 
colorectal carcinoma, including larger tumor size, higher 
histological grade, lymph node metastasis, colorectal 
liver metastasis, advanced stage, and vascular invasion 
[4]. Taken together, our data indicate that reduced 
osteoprotegerin expression is involved in the development, 
progression, and metastasis of colorectal carcinoma, 
suggesting that osteoprotegerin functions as a tumor 
suppressor in colorectal carcinoma. To confirm these 
findings, it will be necessary to analyze osteoprotegerin 
expression using a larger number of primary and 
metastatic colorectal carcinoma tissue samples.
Furthermore, we demonstrated that reduced 
osteoprotegerin expression in colorectal liver metastasis 
predicts the occurrence of recurrent liver metastasis. 
While hepatic resection is the gold standard treatment 
for colorectal liver metastasis and is a safe procedure 
[17], approximately 60-70% of patients undergoing this 
procedure experience disease recurrence, often in the 
first 12-18 postoperative months [18]. Of these patients, 
one-third will have recurrent metastases restricted to the 
liver. Because hepatic resection has become safer through 
improvements in surgical techniques and perioperative 
management, repeat hepatic resection is performed more 
frequently in patients with recurrent liver metastasis 
[19], which may be warranted due to the procedure’s 
expected outcomes that rival those of single hepatic 
resection [20]. Therefore, developing biomarker-based 
criteria to enable earlier and improved stratification of 
Table 2: Relationship between osteoprotegerin expression and patient clinicopathological characteristics
Characteristics  
Number of cases (%)
P value  
Total 
Osteoprotegerin expression status
Reduced Preserved
Age (years) ≥60 42 31 (73.8) 11 (26.2) 0.745
 <60 39 30 (76.9) 9 (23.1)  
Sex Male 56 41 (73.2) 15 (26.8) 0.513
 Female 25 20 (80.0) 5 (20.0)  
Number of metastatic tumor Multiple 35 34 (97.1) 1 (2.9) <0.001*
 Single 46 27 (58.7) 19 (41.3)  
Size of metastatic tumor (cm) ≥2.5 46 34 (73.9) 12 (26.1) 0.738
 <2.5 35 27 (77.1) 8 (22.9)  
Distribution of metastatic tumor Bilobar 23 22 (95.7) 1 (4.3) 0.009*
 Unilobar 58 39 (67.2) 19 (32.8)  
Histological grade of primary 
tumor 3 3 3 (100.0) 0 (0.0) <0.001*
 2 64 54 (84.4) 10 (15.6)  
 1 14 4 (28.6) 10 (71.4)  
Microsatellite instability status MSI 6 3 (50.0) 3 (50.0) 0.338
 MSS 62 46 (74.2) 16 (25.8)  
Recurrent liver metastasis Present 49 45 (91.8) 4 (8.2) <0.001*
 Absent 32 16 (50.0) 16 (50.0)  
Abbreviations: MSI: microsatellite instability, MSS: microsatellite stable; *Statistically significant.
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patients according to their risk of recurrence and survival 
and consequent selection of patients who may benefit 
from repeat hepatic resection is needed [7]. Our findings 
indicate that osteoprotegerin expression in colorectal liver 
metastasis tissues may be such a biomarker, as reduced 
osteoprotegerin expression is a significant independent 
predictor of recurrent liver metastasis. Our data suggest 
that patients harboring colorectal liver metastasis with 
reduced osteoprotegerin expression require careful 
monitoring after hepatic resection for colorectal metastasis 
to facilitate early detection of potentially resectable 
metastatic recurrences.
We observed that reduced osteoprotegerin 
expression is significantly associated with reduced overall 
survival in patients with colorectal liver metastasis. This 
relationship persisted after adjusting for other significant 
clinicopathological characteristics in the multivariate 
analysis, indicating that reduced osteoprotegerin 
expression is an independent prognostic factor for lower 
survival rates in patients with colorectal liver metastasis. 
Similarly, we had previously showed that reduced 
osteoprotegerin expression is an independent predictive 
factor for a poor prognosis in patients with primary 
colorectal carcinoma [4]. Therefore, osteoprotegerin 
Table 3: Factors predicting recurrent liver metastasis
Characteristics   
Univariate Multivariate
Number of cases (%)
P value 
Relative risk
(95% confidence 
interval) 
P value 
Total Recurrent liver metastasis
 Present Absent    
Age (years) ≥60 42 22 (52.4) 20 (47.6) 0.121 Not applicable  
 <60 39 27 (69.2) 12 (30.8)    
Sex Male 56 35 (62.5) 21 (37.5) 0.580 Not applicable  
 Female 25 14 (56.0) 11 (44.0)    
Number of metastatic 
tumor Multiple 35 31 (88.6) 4 (11.4) <0.001*
7.145
(2.015–25.337) 0.002*
 Single 46 18 (39.1) 28 (60.9)    
Size of metastatic 
tumor (cm) ≥2.5 46 30 (65.2) 16 (34.8) 0.319 Not applicable  
 <2.5 35 19 (54.3) 16 (45.7)    
Distribution of 
metastatic tumor Bilobar 23 20 (87.0) 3 (13.0) 0.002*
0.683
(0.062–7.482) 0.683
 Unilobar 58 29 (50.0) 29 (50.0)    
Histological grade of 
primary tumor 3 3 2 (66.7) 1 (33.3) 0.059 Not applicable  
 2 64 42 (65.6) 22 (34.4)    
 1 14 5 (35.7) 9 (64.3)    
Microsatellite 
instability status MSI 6 2 (33.3) 4 (66.7) 0.390 Not applicable  
 MSS 62 37 (59.7) 25 (40.3)    
Osteoprotegerin 
expression status Reduced 61 45 (73.8) 16 (26.2) <0.001*
5.425
(1.443–20.397) 0.012*
 Preserved 20 4 (20.0) 16 (80.0)    
Abbreviations: MSI: microsatellite instability, MSS: microsatellite stable; *Statistically significant.
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Table 4: Factors predicting reduced overall patient survival
Characteristics 
Univariate Multivariate
P value Hazard ratio (95% 
confidence interval)
P value
Age (years) ≥60/<60 0.620 Not applicable  
Sex Male/Female 0.399 Not applicable  
Number of metastatic 
tumor Multiple/Single <0.001* 0.865 (0.356–2.104) 0.749
Size of metastatic 
tumor (cm) ≥2.5/<2.5 0.661 Not applicable  
Distribution of 
metastatic tumor Bilobar/Unilobar 0.026* 1.595 (0.848–3.002) 0.162
Histological grade of 
primary tumor 2–3/1 0.470 Not applicable  
Microsatellite 
instability status MSI/MSS 0.536 Not applicable  
Recurrent liver 
metastasis Present/Absent <0.001* 2.401 (1.203–4.794) 0.013*
Osteoprotegerin 
expression status Reduced/Preserved <0.001* 2.894 (1.272–6.585) 0.011*
Abbreviations: MSI: microsatellite instability, MSS: microsatellite stable; *Statistically significant.
Figure 2: Prognostic significance of osteoprotegerin expression in colorectal liver metastasis. The Kaplan-Meier plot of 
overall survival of patients with colorectal liver metastasis. Reduced osteoprotegerin expression was significantly associated with reduced 
overall survival (P<0.001). The median survival duration of patients with reduced osteoprotegerin expression was 34 months compared to 
92 months in patients with preserved osteoprotegerin expression. Log-rank test.
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expression may be a significant predictor of clinical 
outcomes in patients with colorectal carcinoma with or 
without liver metastasis.
In conclusion, we demonstrated that reduced 
osteoprotegerin expression is significantly associated 
with the extent of colorectal liver metastasis, particularly 
the multiplicity and bilaterality of metastatic tumors. 
Moreover, reduced osteoprotegerin expression was 
independently predictive of the occurrence of recurrent 
liver metastasis after hepatic resection and reduced overall 
survival of patients with colorectal liver metastasis. These 
findings indicate that osteoprotegerin may be a novel 
predictor of recurrent liver metastasis and a prognostic 
biomarker in patients with colorectal liver metastasis. We 
suggest that patients harboring osteoprotegerin-reduced 
colorectal liver metastasis receive careful monitoring 
after hepatic resection for colorectal metastasis to enable 
early detection of potentially resectable recurrent liver 
metastasis.
MATERIALS AND METHODS
Patient and tissue specimens
The 81 patients in this study met the following 
criteria for hepatic resection with curative intent: 
1) medical fitness for major hepatic resection; 2) 
colorectal liver metastasis that resulted in adequately 
sized, well-vascularized hepatic remnants after 
hepatic resection; and 3) no signs of extrahepatic 
metastases in preoperative imaging studies, including 
chest radiography, abdominal ultrasonography, 
abdominopelvic computed tomography, and pelvic 
magnetic resonance imaging [4, 7, 21]. Only patients 
whose metastases were resectable on presentation 
were included. Clinicopathological data, including 
age, sex, number of metastases, size, and distribution 
of colorectal liver metastases, histological grade and 
MSI status of primary colorectal carcinoma, occurrence 
of recurrent liver metastasis, and follow-up time after 
hepatic resection were assessed. No patients underwent 
preoperative neoadjuvant chemotherapy or neoadjuvant 
concurrent chemoradiation therapy. The protocols for the 
use of human tissue were approved by the Institutional 
Review Board of Kangbuk Samsung Hospital, Seoul, 
Republic of Korea (2015-04-053).
The resected tissues were fixed in 10% neutral-
buffered formalin for 24-72 h at room temperature and 
embedded in paraffin blocks. Each formalin-fixed, 
paraffin-embedded block was sectioned at 4-μm thickness 
on a standard rotary microtome, and slices were transferred 
from a water bath on clean slides and stained with 
hematoxylin and eosin. Two pathologists independently 
reviewed the hematoxylin- and eosin-stained slides and 
selected the most representative slide from each case for 
immunohistochemical staining.
Immunohistochemistry
Osteoprotegerin protein expression was assessed 
by immunohistochemistry using a Bond-maX automatic 
immunostainer (Leica Biosystems, Buffalo Grove, IL, 
USA) following the manufacturer’s instructions. The 
general procedure has been previously described [4, 7]: 
4-μm sections of formalin-fixed, paraffin-embedded tissue 
were deparaffinized with Bond Dewax Solution (Leica 
Biosystems), and an antigen retrieval procedure was 
performed using Bond Epitope Retrieval Solution (Leica 
Biosystems) for 30 min at 100°C. Endogenous alkaline 
phosphatase was quenched using Dual Endogenous 
Enzyme Block (Dako, Agilent Technologies Inc., 
Carpinteria, CA, USA) for 5 min, and the samples were 
incubated with rabbit polyclonal anti-osteoprotegerin 
antibody (dilution 1:100; Abcam, Cambridge, MA, 
USA) for 30 min. Slides were then incubated in post-
primary AP (Bond Polymer Refine Red Detection, Leica 
Biosystems) for 20 min, followed by incubation for 30 
min in polymer AP (Bond Polymer Refine Red Detection, 
Leica Biosystems). Sections were then counterstained 
with hematoxylin. Slides were dehydrated following 
a standard procedure and sealed with coverslips. To 
minimize interassay variation, positive and negative 
control samples were included in each run. The positive 
control was normal liver tissue, and the negative control 
was prepared by substituting non-immune serum for the 
primary antibody; no detectable staining was evident.
Evaluation of immunohistochemical staining
Immunohistochemical staining was independently 
analyzed by two pathologists who were blinded to the 
clinicopathological data and outcomes of the patients. 
Osteoprotegerin staining intensity was graded as negative 
(0), weak (1+), moderate (2+), or strong (3+) as previously 
described [4, 7, 21, 22]. No heterogeneous staining was 
observed within individual slides, and estimation of the 
proportion of staining was not required. Disagreements 
between the two pathologists were resolved by consensus.
Statistical analysis
A Chi-squared test or Fisher's exact test was 
performed to determine whether osteoprotegerin 
expression was associated with clinicopathological 
characteristics of patients with colorectal liver metastasis. 
Multivariate logistic regression analysis with a backward 
stepwise elimination method was used to identify 
independent significant predictors of recurrent liver 
metastasis. Univariate and multivariate survival analyses 
were used to determine the prognostic implications of 
osteoprotegerin expression. Curves for overall survival 
were drawn according to the Kaplan-Meier plot, and 
differences were analyzed by applying the log-rank test 
for univariate survival analysis. Multivariate survival 
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analysis using the Cox proportional hazard model (95% 
confidence interval) with a backward stepwise elimination 
method was also performed. All covariates with statistical 
significance upon univariate analysis were entered into 
the multivariate analysis. The least significant covariates 
were removed from the model by backward stepwise 
elimination. Statistical analyses were performed using 
PASW Statistics for Windows (version 18.0; Armonk, NY, 
USA). Statistical significance was defined as a P value less 
than 0.05.
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